GENEART AG

Field of operations

GENEART provides integrated system solutions for DNA engineering and processing based on the gene synthesis technology platform to deliver improved drugs and biotech products. The services portfolio ranges from the production of optimized synthetic genes and the generation of gene variants and gene libraries in combinatorial biology (gene evolution) right through to the production of DNA-based agents.

Markets and business areas

GENEART's services are utilized by pharmaceutical and biotech companies, and research institutes on the following markets:

Red Biotechnology:

DNA-based drugs and recombinant vaccines
Protein drugs

White Biotechnology:

Biocatalysts (enzymes, e.g. for industrial processes and consumer goods)

Green Biotechnology

Production of biopharmaceuticals in plants
Transgenic plants

Technology and Services

Gene optimization and gene synthesis
Based on its proprietary GeneOptimizer™ sequence design software (patent pending), GENEART optimizes genes according to client demands. The interdisciplinary gene synthesis process combines bioinformatics, organic chemistry and molecular biology to deliver a quality-assured, documented gene optimized for the specific application within 2 - 4 weeks. DNA molecules are manufactured under license from F. Hoffmann-La Roche Ltd. The entire gene synthesis process is certified to DIN ISO 9001:2000.

Gene evolution services
Taking a master gene as its starting point, GENEART's GeneEvolution business unit can generate individual gene variants, and specific or randomized gene libraries.

Research-grade plasmid production and manufacture of DNA-based agents (cGMP)
For more in-depth research and development, GENEART supplies different scales of plasmid-encoded genes and gene variants in the required quantity and quality – right up to cGMP grade.

Legal form

Listing

Open Market (Entry Standard) Frankfurt Stock Exchange

Employees

>140

Management Board

Prof. Dr. Ralf Wagner, CEO, CSO
Christian Ehl, CEO, CFO

Subvisory Board

Dr. Farsin Yadegardjam, Chairman
Bertram Gilka-Bötzow, Vice Chairman
Prof. Dr. Hans Wolf

Cooperation partners

TakaraBio, Japan (cooperation on sales)
HyLabs, Israel (cooperation on sales)
GENOVAC GmbH (cooperation on sales and technology)

Company targets

GENEART is fully committed to its goal of establishing itself on the international market as the leading provider of system solutions for the pharmaceutical and biotech industry in the field of gene synthesis and downstream DNA processing (DNA engineering and processing) and as a major license partner. The company aims to achieve this by constantly developing its range of products and services in the field of DNA directed evolution. In addition, GENEART also specializes in the development and manufacture of DNA-based agents.

Contact

Headquarters:

GENEART AG
BioPark Regensburg
Josef-Engert-Straße 11
D-93053 Regensburg
phone:   +49-941-942 76-0
fax:         +49-941-942 76-711
info@geneart.com
www.geneart.com

GENEART Inc.
1243 Islington Ave, Suite 705
Toronto, ON
Canada M8X 1Y9
us-office@geneart.com
phone: +1-416-233-0666
fax: +1-416-233-0854

PDF